Becton, Dickinson and Company (BDX) Stake Boosted by Parsons Capital Management Inc. RI

Parsons Capital Management Inc. RI increased its position in Becton, Dickinson and Company (NYSE:BDX) by 7.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,024 shares of the medical instruments supplier’s stock after buying an additional 335 shares during the period. Parsons Capital Management Inc. RI’s holdings in Becton, Dickinson and were worth $922,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. North Star Investment Management Corp. increased its stake in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the period. Crestwood Advisors Group LLC bought a new stake in Becton, Dickinson and during the first quarter worth approximately $101,000. Almanack Investment Partners LLC. bought a new stake in Becton, Dickinson and during the first quarter worth approximately $105,000. Parkside Financial Bank & Trust increased its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the period. Finally, Financial Architects Inc increased its stake in Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the period. Institutional investors own 75.57% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) traded down 0.70% on Friday, hitting $197.91. 391,488 shares of the stock traded hands. The stock has a market capitalization of $45.04 billion, a P/E ratio of 57.32 and a beta of 1.05. The company’s 50 day moving average price is $199.60 and its 200-day moving average price is $188.53. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the prior year, the company posted $2.35 EPS. The company’s revenue was down 5.1% compared to the same quarter last year. Analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/18/becton-dickinson-and-company-bdx-stake-boosted-by-parsons-capital-management-inc-ri.html.

A number of research firms have commented on BDX. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Cowen and Company reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday. Barclays PLC reaffirmed an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday. Finally, Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $195.79.

In other news, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now directly owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total value of $1,240,622.24. Following the completion of the sale, the insider now directly owns 15,648 shares of the company’s stock, valued at $3,157,140.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,631 shares of company stock valued at $11,112,178. 1.40% of the stock is currently owned by company insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit